BAX vs. EW, DXCM, IDXX, RMD, STE, HOLX, PODD, TFX, GMED, and MASI
Should you be buying Baxter International stock or one of its competitors? The main competitors of Baxter International include Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry.
Edwards Lifesciences (NYSE:EW) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends.
Edwards Lifesciences received 584 more outperform votes than Baxter International when rated by MarketBeat users. Likewise, 71.85% of users gave Edwards Lifesciences an outperform vote while only 66.12% of users gave Baxter International an outperform vote.
Edwards Lifesciences currently has a consensus price target of $95.06, suggesting a potential upside of 10.41%. Baxter International has a consensus price target of $44.42, suggesting a potential upside of 35.05%. Given Edwards Lifesciences' higher probable upside, analysts clearly believe Baxter International is more favorable than Edwards Lifesciences.
Edwards Lifesciences has a net margin of 23.01% compared to Edwards Lifesciences' net margin of 17.79%. Baxter International's return on equity of 22.86% beat Edwards Lifesciences' return on equity.
79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 1.3% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 0.2% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Baxter International has higher revenue and earnings than Edwards Lifesciences. Baxter International is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
Edwards Lifesciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.
In the previous week, Edwards Lifesciences had 6 more articles in the media than Baxter International. MarketBeat recorded 14 mentions for Edwards Lifesciences and 8 mentions for Baxter International. Baxter International's average media sentiment score of 1.00 beat Edwards Lifesciences' score of 0.87 indicating that Edwards Lifesciences is being referred to more favorably in the media.
Summary
Edwards Lifesciences beats Baxter International on 13 of the 18 factors compared between the two stocks.
Get Baxter International News Delivered to You Automatically
Sign up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Baxter International Competitors List
Related Companies and Tools
